Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 3 for:    bbt877

Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04138849
Recruitment Status : Completed
First Posted : October 25, 2019
Last Update Posted : January 18, 2020
Sponsor:
Collaborator:
KCRN Research, LLC
Information provided by (Responsible Party):
Bridge Biotherapeutics, Inc.

Brief Summary:
This study will collect safety, pharmacokinetic, and pharmacodynamic data in Japanese male subjects in order to support development worldwide.

Condition or disease Intervention/treatment Phase
Healthy Participants Drug: BBT-877 single dose Drug: Placebo single dose Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 Following Single Doses in Healthy Japanese Male Subjects
Actual Study Start Date : October 1, 2019
Actual Primary Completion Date : October 25, 2019
Actual Study Completion Date : October 25, 2019

Arm Intervention/treatment
Experimental: BBT-877 Low Dose Drug: BBT-877 single dose
Oral capsule, single dose.

Experimental: BBT-877 Mid Dose Drug: BBT-877 single dose
Oral capsule, single dose.

Experimental: BBT-877 High Dose Drug: BBT-877 single dose
Oral capsule, single dose.

Placebo Comparator: Placebo Drug: Placebo single dose
Oral capsule, single dose.




Primary Outcome Measures :
  1. Adverse events (AEs) [ Time Frame: Up to Day 14. ]
    The number of AEs.


Secondary Outcome Measures :
  1. Pharmacokinetics_AUC (the area under the curve) [ Time Frame: Day 1 to Day 4 ]
    AUC of BBT-877

  2. Pharmacokinetics_Cmax (peak concentration) [ Time Frame: Day 1 to Day 4 ]
    Cmax of BBT-877

  3. Pharmacodynamics_plasma LPA (Lysophosphatidic acid) [ Time Frame: Day 1 to Day 4 ]
    plasma LPA (18:2 and 20:4) concentrations over time and percent decrease from baseline LPA level



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Signed the informed consent form as described in Appendix 3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
  2. Healthy male 18 to 55 years of age inclusive at the time of signing the informed consent form
  3. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to dosing and throughout the study.
  4. Overtly healthy as determined by medical evaluation including medical history, physical examination, clinical laboratory tests
  5. Body mass index (BMI) within 18 to 30.0 kg/m2 (inclusive) and body weight not less than 50 kg
  6. Blood pressure (after supine for 5 minutes) between 90 and 140 mmHg systolic, inclusive, and no higher than 90 mmHg diastolic.
  7. A 12-lead electrocardiogram (ECG) consistent with normal cardiac conduction and function.
  8. Must agree to use contraception as detailed in Appendix 5 of this protocol during the treatment period and for at least 90 days after dosing of study treatment and refrain from donating sperm during this period
  9. Be first generation Japanese.

Exclusion Criteria:

  1. Has a history of or current clinically significant medical illness that the investigator considers should exclude the subject or that could interfere with the interpretation of the study results.
  2. Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening and Day -1 as deemed appropriate by the investigator
  3. Clinically significant abnormal physical examination, vital signs or 12 lead ECG at screening and Day -1 as deemed appropriate by the investigator
  4. Has donated blood or had a significant blood loss (≤500 mL) within 8 weeks of Day 1 or history of anemia or history of decreased red blood cells (RBC).
  5. Donated plasma within 7 days of Day -1
  6. Estimated creatinine clearance <80 mL/min
  7. Liver function tests (serum alkaline phosphatase [ALP], aspartate transaminase [AST], alanine aminotransferase [ALT]) and serum bilirubin (total and direct) 1.2 times above the upper limit of normal (ULN) at Screening or Day -1.
  8. Baseline hemoglobin, hematocrit, red blood cell count below the lower limit of normal at Screening and Day -1.
  9. Has a history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV; has a history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HBsAg or anti-HCV at Screening.
  10. History of drug or alcohol abuse according to Diagnostic and Statistical Manual of Mental Disorders (4th edition) criteria within 5 years before screening or positive test result(s) for alcohol and/or drugs of abuse at screening and Day -1.
  11. Positive cotinine test at Screening and Day -1.
  12. History of presence of hypersensitivity or idiosyncratic reaction to the study drug(s) or related compounds.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04138849


Locations
Layout table for location information
United States, California
WCCT
Cypress, California, United States, 90630
Sponsors and Collaborators
Bridge Biotherapeutics, Inc.
KCRN Research, LLC
Investigators
Layout table for investigator information
Study Director: Jeong-Hyun Ryou, M.D., Ph.D. Bridge Biotherapeutics, Inc.

Layout table for additonal information
Responsible Party: Bridge Biotherapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04138849    
Other Study ID Numbers: BBT877-IPF-003
First Posted: October 25, 2019    Key Record Dates
Last Update Posted: January 18, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No